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ABSTRACT
Objectives: The present study describes a disposable static diffusion cell for in vitro diffusion studies to achieve better results as compared to well 
existing Franz diffusion cell (FDC) in terms of the absence of bubbles, variable receptor compartment, ease of handling, and faster results.
Materials and Methods: The cell consists of a cup-shaped donor compartment made of semi permeable that could be either cellophane membrane 
or, animal skin fitted to a rigid frame, which is supported on a plastic plate that contains a hole for the sample withdrawal. The receptor compartment 
is a separate unit, and it could be any container up to 500ml volume capacity. The most preferred receptor compartment is glass beaker. In the 
present study, goatskin was used as semi-permeable membrane and verification of its performance was carried out through diffusion studies using 
gel formulations of one each of the four-selected biopharmaceutical classification system (BCS) class drugs. Metronidazole, diclofenac sodium, 
fluconazole, and sulfadiazine were used as model drugs for BCS Class I, II, III, and IV, respectively.
Results: The newly developed diffusion cell (NDDC) was found to provide faster and more reproducible results as compared to FDC. At the time 
interval of 24 h, the cell was found to exhibit a higher diffusion of metronidazole, diclofenac sodium, fluconazole, and sulfadiazine by 0.65, 0.65, 0.32, 
and 0.81 folds, respectively. The faster release obtained with NDDC was attributed to a larger surface area of skin as compared to that in FDC.
Conclusion: It was concluded that better reproducibility of results could be achieved with NDDC.
Keywords: Newly developed diffusion cell, Franz diffusion cell, Biopharmaceutical classification system, Metronidazole, Diclofenac sodium, 
Fluconazole, Sulfadiazine.
INTRODUCTION
Among the drug delivery systems, transdermal drug delivery offers 
avoidance of first-pass metabolism, decreased toxicity, fewer side effects, 
as well as greater patient compliance [1,2]. To evaluate the performance 
of prepared transdermal formulation in vitro static diffusion cells are used. 
This diffusion study helps the scientists to understand the relationship 
between skin, drug, and formulation [3,4]. This further helps to optimize 
the formulation and process variables for optimizing the formulation as 
well as help to assess the toxicity of the drug [5-8]. The most common 
technique for measuring dermal absorption in vitro is the application of 
the test substance in an appropriate formulation to the surface of a skin 
sample, which is mounted as a barrier between the donor compartment 
and receptor compartment of a diffusion cell [9]. Diffusion cells may be of 
static [3] or flow-through [10]. Static diffusion cells sample this chamber 
and replace with new perfusate at each time point. Flow-through cells use 
a pump to pass perfusate through the receptor chamber and collect flux 
by repeatedly collecting perfusate [9]. Static diffusion cells can be sub-
divided on the basis of the skin orientation: The membrane can be placed 
horizontally or vertically. The majority of skin absorption studies are 
conducted using horizontal cells, with the skin surface open to the air. The 
use of vertical (or side-by-side) cells is more common when evaluating drug 
delivery systems such as sonophoresis, iontophoresis, or electroporation 
and requires immersion of both surfaces of the skin preparation, which 
may result in excessive hydration and possibly skin damage [11].
One of the most widely used static designs for studying in vitro 
permeation is the Franz diffusion cell (FDC) [12]. FDC comprises a 
donor chamber, an upper chamber through which the drug formulation 
to be studied/tested is placed into the device/cell. The chamber is 
attached to a flat ground glass joint. Another component is semi-
permeable membrane which is the “functional” part of the device and 
comprises. In general, regenerated cellulose membrane is used, due to 
good permeability and resistance to various organic solvents/buffers. 
The membrane is placed horizontally between the donor chamber and 
receptor chamber and held in place by means of a clamp. The lower part 
of FDC is receptor chamber, which contains buffer/water, into which the 
drug diffuses. The chamber is surrounded by a “water jacket” through 
which heated water is circulated by means of a heater/circulator and 
helps to maintain the temperature of buffer/water inside the receptor 
chamber, constant simulating the body temperature. To measure the 
rate of drug diffusion across the semi-permeable membrane, from 
the “donor chamber” into the “receptor chamber,” sampling of the 
solution inside the receptor chamber has to be carried out, at regular 
time intervals. A “sampling port” is provided in the form of an “arm” 
through which the “solution” can be simply withdrawn with the help 
of a needle/syringe [3]. Water/buffer inside the receptor chamber is 
stirred gently by means of a stirring arrangement, which comprises a 
magnetic bar placed inside the receptor chamber. The assembly is then 
placed over a magnetic stirrer so that the bar rotates and helps to stir 
the solution.
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Although FDC is immensely popular and is considered the golden 
standard for performing drug permeation studies, it suffers from the 
following serious limitations of restricted sink volume, restricted 
membrane area, slow, cumbersome, and laborious handling and 
problem of air-bubbles.
Yang and Imbert (2008) and Yang and Imbert (2011) reported 
an improved static diffusion cell, in which a bubble-trap has been 
introduced, and the cell was compact. However, it still suffered from 
the limitation of a dedicated receptor compartment having a sidearm 
for sample collection and also having a very limited and fixed volume 
which cannot be altered [11,13]. In another study, Mohammad 
reported a static diffusion cell utilizing fresh corneas, for transcorneal 
drug penetration studies. It had means to create pressure within the 
chamber, to simulate intraocular pressure in the human eye of 20–22 
mm-Hg. The major limitation was that the cell was quite complicated, 
required use of fresh corneas involving sacrifice of animals and the 
entire assembly was of fixed size, restricting flexibility of experimental 
design and also the sink volume [14]. Joseph et al. reported improved 
FDC for evaluation of gel formulations for topical drug delivery [15]. 
However, the basic limitations of the FDC, i.e., limited membrane area 
and restricted receptor chamber volume were not overcome. Castro 
et al. reported transdermal diffusion cell testing arrangement and 
methods but the basic component of FDC remained unchanged [16]. 
The size of the receptor chamber was also fixed, and the membrane 
surface area was also limited [16].
The present study describes a disposable static diffusion cell for in vitro 
diffusion studies to achieve better results as compared to well existing 
FDC in terms of the absence of bubbles, variable receptor compartment, 
ease of handling, and faster results. To check the effectiveness of newly 
designed diffusion cell (NDDC), drug from each biopharmaceutical 
classification system (BCS) class of drugs was selected, and their gel 
formulations were prepared. Their diffusion profiles were compared 
through goatskin using NDDC as well as FDC.
MATERIALS AND METHODS
Materials
Metronidazole, fluconazole, and sulfadiazine were procured from 
Jackson Laboratories (Pvt.) Ltd., Punjab, India. Diclofenac sodium was 
gifted by Rydberg Pharmaceutical, Dehradun, India. Hydroxypropyl 
methylcellulose (HPMC) K15M was gifted by Colorcon (Pvt.) Ltd., 
Bengaluru, India. Potassium dihydrogen orthophosphate, hydrochloric 
acid, and dimethylformamide were purchased from central drug house 
Pvt., Ltd., Mumbai, India. Sodium hydroxide pellets were purchased 
from Loba Chemie Pvt. Ltd., Mumbai, India. Triethanolamine was 
purchased from Molychem, Babu Genu Road, Mumbai, India. Triple 
distilled water was used throughout the study.
Methods
Preparation of gel formulation for permeation studies
A 1% w/v gel of the drugs, metronidazole, diclofenac sodium, 
fluconazole, and sulfadiazine were prepared individually using HPMC 
K15Mas gelling agent. The preparation was allowed to stand, permitting 
entrapped air to separate. Then, triethanolamine was added dropwise 
to neutralize the gel. The formula for the gel preparation is shown in 
Table 1.
Design of the novel static diffusion cell and its comparison with 
FDC
The presented diffusion cell is a disposable static diffusion cell made 
mainly from plastic. The improved cell and its various components are 
depicted in Fig. 1. The improved diffusion cell comprises the following 
parts:
Donor chamber
Unlike the FDC, where the donor chamber and the membrane are 
separate parts and need to be assembled, in new diffusion cell, the 
donor chamber, and membrane form an “integrated part” and no 
assembling is needed. The donor chamber comprises a plastic ring 
(1) to which is attached a membrane sac (2), such that the interior 
of the plastic ring and the open end of the membrane sac are in flow 
communication with each other. This semi-permeable membrane could 
be replaced by animal’s skin or, any other cellular membrane. This 
enables easy holding and handling. Unlike the FDC where membrane is 
stretched across an opening, in the new cell, it is in the form of a “sac” 
attached to a hard rim. The drug formulation is applied inside the sac.
Bi-functional disc
Comprises a flat plastic plate having two apertures - a larger central 
aperture (4) and a smaller lateral aperture (5). The sac is simply placed 
over the rim of the central aperture and does not require any clamp 
to hold it. The sac dips into the solution in the receptor chamber. The 
smaller, laterally positioned aperture (5), acts as a sample collection 
port through which a pipette (9) is inserted for a sampling of solution 
(7) in the receptor chamber (6), for withdrawing the sample.
Receptor chamber
This is the lower chamber (6), which contains the medium (7) into 
which the drug diffuses. It is an ordinary glass beaker. It can be placed 
over a magnetic stirrer with a heating plate to maintain the medium at 
a constant temperature. The receptor chamber is thus not an essential 
part of the assembly and is separate. Depending on the solubility and 
permeability characteristics of the drug molecule (BCS class) and 
Table 1: Composition of gel formulation
S. No Name of drug BCS class Quality of drug (g) pH 5.0 acetate buffer DMF* HPMC K15M Purified water
1 Metronidazole I 0.5 45 - 1 Quantity sufficient to 50 ml
2 Diclofenac II 0.5 45 - 1
3 Fluconazole III 0.5 45 - 1
4 Sulfadiazine IV 0.5 45 9 1
BCS: Biopharmaceutical classification system, HPMC: Hydroxypropyl methylcellulose
Fig. 1a: Fully assembled newly developed diffusion cell 
in operation, Fig. 1b: Integrated donor chamber (1) with 
permanently attached membrane sac (2), Fig. 1c: Bi-functional 
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the body compartment which is to be simulated, a beaker of suitable 
volume can be selected as the receptor compartment.
Stirring arrangement
This comprises a magnetic bar (8) placed inside the receptor chamber 
which stirs the solution at the required rpm.
Sampling arrangement
Unlike the FDC where a “sampling port” is provided in the form of an 
“arm” through which the “solution” can be withdrawn with the help 
of a needle and syringe, sampling arrangement in the cell of the new 
design is quite different. The disc comprises a “hole” (5) through which 
a pipette (9) can be inserted, and the sample can be withdrawn. As a 
result, the problem of bubbles is altogether eliminated.
Ex vivo diffusion studies using FDC
Ex vivo diffusion study of prepared gel formulations was carried out 
using freshly isolated goat abdominal skin, collected from slaughterhouse 
in saline. The hairs of goatskin were removed using scissor followed by 
marketed hair remover. Skin was then washed with distilled water to 
remove the mucous and other adhered matrices. Additional fat layer was 
removed from the skin using scalpel blade. Skin of about 0.2 mm thickness 
and 3 cm length were mounted on FDC having a surface area of 1.79 cm2and 
volume of 25 mL. The skin was stabilized using acetate buffer (pH 5.0) in 
both, donor and receptor compartments with magnetic stirring for 30 min. 
At the end of 30 min, the existing buffers in both the compartments were 
replaced with fresh buffer. Prepared gel formulation (1 g) containing drug 
of different classes was placed individually on to the donor compartment. 
The study was carried out for 24 h, and at predetermined time intervals, 
samples were withdrawn from the receptor compartment. Withdrawn 
samples were filtered through 0.45 µm membrane filter and analyzed 
for drug concentration using ultraviolet (UV)-visible spectrophotometer 
at 315 nm for metronidazole, 276 nm for diclofenac sodium, 265 nm for 
fluconazole, and 258 nm for sulfadiazine, respectively. Each study was 
carried out in triplicate and mean data were recorded. The permeation 
profile was constructed by plotting amount of drug permeated per unit 
skin surface area (µg/cm2) versus time (h). The steady state flux (Jss, mcg/
cm2 h) was calculated from the slope of the linear portion of the plot using 
linear regression analysis [17].
The entire procedure for preparation of skin for diffusion studies using 
FDC is depicted in Fig. 2.
Skin permeation studies using newly developed diffusion cell 
(NDDC)
Skin permeation studies were performed on NDDC (effective surface 
diameter 7.4 cm, volume 260 ml, area 11.618 cm2, Excellion Innovations 
Co., Ltd., India). The skin was brought to room temperature and 
mounted between the donor and receptor compartments of the 
diffusion cells where the epidermal faced upward and the dermal 
side faced downward. The residues were trimmed. Initially, the donor 
compartments were empty, and the receiver chamber was filled 
with degassed acetate buffer (pH 5.0). The receptor fluid was stirred 
magnetically at a speed of 50 rpm, and the assembled apparatuses 
were adjusted and maintained at 32°C with the aid of digital thermo 
controller. After equilibration for 30 min, the 1 g of prepared gels were 
applied on the skin sheet of donor compartment of NDDC. Samples 
were withdrawn at predetermined time intervals and replenished with 
10 mL fresh degassed buffer. Prepared gel formulation (1 g) containing 
drug of different classes was placed individually on to the donor 
compartment. The study was further followed as per the procedure 
mentioned for FDC. The experiments were repeated in triplicate and 
mean data were recorded. The scheme of preparation of skin for drug 
permeation studies using newly diffusion cell is shown in Fig. 3.
Specificity studies
To check the interaction of the drug with skin and the excipients used in 
the formulation, the study was conducted in which the drug was mixed 
Fig. 2: Cutting of hair (a): Removal of hair using hair remover (b): Removal of fatty mass using scalpel (c): Measurement of diameter of 
semipermeable membrane used as donor compartment for Franz diffusion cell (FDC) (d-f): Application of gel to the donor compartment 
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with skin homogenate and the excipients used in the formulation. 
Finally, pure drug solution, skin homogenate, drug solution containing 
skin homogenate, drug solution mixed with placebo solution, and 
placebo solution were scanned in UV spectrophotometer at the 
absorbance maxima of all the selected drugs.
Statistical analysis of data
All the data were statistically analyzed by analysis of variance using 
INSTAT 1 software. Results are quoted as significant where P < 0.05. 
Fig. 4: Diffusion study of metronidazole
Fig. 5: Diffusion study of diclofenac sodium
Values of the coefficient of variation were calculated for each reading to 
have an idea about the reproducibility of results.
RESULTS AND DISCUSSIONS
Ex vivo skin permeation studies
The comparison of mean percentage cumulative drug release for 
metronidazole, diclofenac sodium, fluconazole, and sulfadiazine in FDC 
and novel diffusion cell is shown in Figs. 4-7. The mean percentage 
cumulative drug release after 24 h study for FDC was found to be 
81.21%, 48.88%, 80.88%, and 41.28% for metronidazole, diclofenac 
sodium, fluconazole, and sulfadiazine, respectively. Whereas, with 
Fig. 3: (a): Removal of hair using hair remover (b): Removal of fatty mass using scalpel (c): Measurement of diameter of semipermeable 
membrane used as donor compartment for newly developed diffusion cell (d): Measurement of skin diameter exactly as that of semi-
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NDDC mean percentage cumulative drug release after 24 h study was 
found to be 98.96%, 75.14%, 95.14%, and 61.14% for metronidazole, 
diclofenac sodium, fluconazole, and sulfadiazine, respectively. The 
T50% (time at 50% drug got released) drug release was observed at 
5 h, 9 h, 5 h, and 9 h for metronidazole, diclofenac sodium, fluconazole, 
and sulfadiazine, respectively. However, the T50% drug release was 
only observed for metronidazole (6 h) and fluconazole (8 h) in any 
of the studies carried out using FDCs even after 24 h. The T50% drug 
release is shown in Table 2.
Cell dimension evaluation
The skin effective surface diameter was calculated using measurement 
plastic scale (Polo, India) exactly same of the semi-permeable 
membrane used in NDDC and FDC. The effective surface area of NDDC 
was found to be 11.618 cm2 and of FDC was found to be 1.79 cm2. The 
effective surface area of NDDC is about 10 times more than that of FDC. 
This could be one of the reasons for the enhanced diffusion of drugs 
through NDDC.
The drug diffusion studies carried out on different BCS class drugs 
using FDC and NDDC revealed that mean percentage cumulative 
drug release was greater in NDDC as compared to FDC. The test of 
significance showed that the P value of mean percentage cumulative 
drug release between FDC and NDDC is < 0.05 (i.e. P = 0.008, 0.004, 
0.0001, and 0.0001 for metronidazole, diclofenac sodium, fluconazole, 
and sulfadiazine gels, respectively) as shown in Figs. 4-7. This reveals 
that there is a significant difference in the drug release of all the drugs 
in FDC and NDDC. It was observed that 0.82-fold increase in the release 
of sulfadiazine and 0.75-fold increase in the release of diclofenac 
sodium through NDDC as compared to FDC. However, folds increase 
in the release of fluconazole and 0.65-fold increase in the release of 
metronidazole were observed through NDDC as compared to FDC 
respectively.
The higher percentage drug release in the improved cell is attributed 
to two factors:
Higher membrane surface area
This is due to the presence of membrane sac instead of flat membrane, 
which leads to greater exposure of drug mounted on membrane sac, to 
the receptor compartment as compared to FDC.
Higher receptor cell volume
In FDC only 30–100 ml of liquid can be filled in the receptor compartment, 
while in case of the improved cell, volume of up to 10 times can be used 
in the receptor compartment. Due to the small volume of liquid in the 
FDC, equilibrium between the donor and receptor compartments is 
achieved within a short period of time, and this stops the permeation 
of drug from donor to receptor compartment. However, in case of the 
improved cell, due to much higher volume, equilibrium is not reached 
easily, and drug continues to diffuse very fast.
Table 2: Data showing T50% drug release from gel formulation 
of different BCS class drugs using diffusion cell NDDC and FDC
Drug T50% (h)
NDDC FDC
Metronidazole gel 5.0 6.8
Diclofenac sodium gel 9.0 -
Fluconazole gel 5.0 8.0
Sulfadiazine gel 9.0 -
NDDC: Newly developed diffusion cell, FDC: Franz diffusion cell
Fig. 6: Diffusion study of fluconazole
Fig. 7: Diffusion study of sulfadiazine
Fig. 8: Overlay spectrum of metronidazole, skin, and placebo
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Fig. 9: Overlay spectrum of diclofenac sodium, skin, and placebo
Fig. 10: Overlay spectrum of fluconazole, skin, and placebo
Fig. 11: Overlay spectrum of fluconazole, skin, and placebo
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One of the major problems with FDC has been the high value of variation 
in the results. This can be attributed to the formation of air bubbles 
and non-sink conditions in receptor phase due to a limited volume. The 
problems of lack of reproducibility were experienced in our studies 
using FDC also.
Specificity studies
The overlay of spectra of specificity studies of metronidazole, diclofenac 
sodium, fluconazole, and sulfadiazine are shown in Figs. 8-11. It was 
observed from the scan that there was no interaction of drug, excipients, 
and skin. Hence, the study was specific for the estimation of those drugs.
CONCLUSION
The NDDC has been found to offer certain advantages over the 
conventional static diffusion cells. During handling the cells were found 
to be less cumbersome to handle and free from breakability. The release 
studies were found to be much faster as compared to conventional 
diffusion cells. The higher release in shorter time was found to give 
the higher discriminatory ability to the method. No bubble formation 
was observed during the conduct of the experiments in the NDDC. The 
reproducibility of results in the term percentage coefficient of variance 
was found to be considerably better with NDDC as compared to those 
with FDC. The study will further be extended to evaluate the same 
parameters of diffusion through various animal membranes to make 
the use of the cell more comprehensive.
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